Raytec Bio Completes Tens of Millions Series A Financing Led by Huimei Capital to Advance Ophthalmic Regenerative Medicine Innovations

VCBeat learned that recently, Guangzhou Raytec Biotechnology Co., Ltd. ("Raytec Biotechnology"), an innovative medical device company specializing in ophthalmic regenerative medicine, announced the completion of a multi-million yuan Series A round of financing led by HM CAPITAL, with participation from Nanjing Ruiyuan, Guangzhou Industry Investment, and other institutions.

After the completion of this round of financing, Raytec Biotechnology will increase the marketing and promotion efforts for its existing products. At the same time, it will continue to invest heavily in the research and development of new products and fully advance the clinical trials and applications of products under development, accelerating the launch of new products.

Raytec Biotechnology was founded in September 2014 as an innovative medical device company specializing in ophthalmic regenerative medicine, integrating research and development, production, and sales. The company has independently developed China's first exclusive wet biological amniotic membrane (Ruixiu Fu).^®) was launched in April 2020. This product is an active biomaterial capable of addressing various ophthalmic conditions from the ocular surface to the fundus. With over 15 application areas, its most widely used application is currently ocular surface reconstruction. Due to meeting the critical needs of ophthalmic clinical practice, within just over a year of its launch, the product has been listed in 24 provinces and quickly covered more than 200 tertiary hospitals across China, including well-known chain ophthalmology institutions such as Aier Group, Huaxia Group, and Heshi Ophthalmology Group, with sales showing exponential growth. Meanwhile, Raytec Biotechnology boasts a robust pipeline, with multiple products ready to enter clinical trials, covering areas such as ocular surface injuries, dry eye, glaucoma, macular holes in the fundus, and optometry. Through the dual drivers of strong "in-house R&D capabilities + global BD exploration" and a comprehensive closed-loop system encompassing R&D, product registration, and market sales, Raytec Biotechnology has become a leading innovative technology and service platform in China's ophthalmic medical device field.

Dr. Lin Yongliang, founder of Raytec Biotechnology, has over 15 years of experience in the research and development of implantable regenerative medical devices. He has focused on overcoming key technical challenges and processes related to the industrial transformation of regenerative medical implants. He has led and undertaken several national or provincial key R&D projects, with more than 60 R&D and transformation projects involved and 15 authorized invention patents.

Mr. Xu Hao, Co-founder of Raytec Biotechnology, has over two decades of experience in sales management of ophthalmic drugs and medical device products. He has served as the sales head at companies such as Merck, Pfizer, and Shenzhen Ruilin. The elite marketing team he leads specializes in academic promotion and focuses on the specialized field of ophthalmology with a professional sales force.

Dr. Lin Yongliang said:We sincerely thank HM CAPITAL, Nanjing Ruiyuan, and Guangzhou Industrial Investment for their support in this round of financing. Raytec Biotechnology will take this as an opportunity to accelerate the research and development and implementation of its products in the pipeline. Raytec Biotechnology's Ruixiu Recovery^®In ophthalmic clinical treatment, it has an excellent reputation, broad prospects, and there will be iterative products launched in the future. Meanwhile, Raytec Biotechnology owns an experienced sales team in the ophthalmology field with strong product promotion capabilities, which is one of the company's core competencies.

HM CAPITAL stated:Driven by the intensifying aging population, the demand for ophthalmic medical services is growing rapidly. HM CAPITAL has high expectations for Raytec Biotechnology's understanding of the ophthalmic medical device field and its clinically validated product development capabilities. Currently, several products under development by Raytec Biotechnology can effectively fill the gaps in the current eye disease treatment market. Moreover, the ophthalmology industry exhibits strong consumer healthcare attributes, and the company’s product line in the vision care sector also holds significant potential to quickly expand market capacity. It is believed that in the near future, more of its products will be developed and launched.